The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Heart Problem Pauses Hepatitis C Drug Study

Back to News Homepage

Next

Vitamin B12 During Hepatitis C Treatment

Hep C Trial with Sovaprevir Has 85% Success Rate

Print this page

In a mid-stage trial, Achillion’s experimental drug, sovaprevir, demonstrated an excellent efficacy rate and safety profile.

Achillion hepatitis C drug shows promise in mid-stage study

Tue Aug 7, 2012 8:37pm EDT

(Reporting by Zeba Siddiqui in Bangalore; Editing by Anthony Kurian)

(Reuters) – Achillion Pharmaceuticals Inc said its experimental hepatitis C drug showed promising interim data in a mid-stage trial, sending its shares higher in extended trade.

The company said the drug sovaprevir, when given along with the standard therapy of pegylated interferon and ribavirin, showed no detectable virus level in a majority of patients four weeks after the end of the treatment period.

Of the 39 patients who received 12 weeks of additional standard therapy following 12 weeks of the combination therapy, a total of 33 patients in three different dosage arms showed sustained viral response a month later.

Continue reading this entire article:
http://www.reuters.com/article/2012/08/08/us-achillon-hepatitisstudy-idUSBRE87700320120808

15 Comments
Share
Share

Previous

Heart Problem Pauses Hepatitis C Drug Study

Back to News Homepage

Next

Vitamin B12 During Hepatitis C Treatment

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.